192 related articles for article (PubMed ID: 24982772)
1. The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?
Thomas TO; Hasan S; Small W; Herman JM; Lock M; Kim EY; Mayr NA; Teh BS; Lo SS
J Gastrointest Oncol; 2014 Jun; 5(3):236-46. PubMed ID: 24982772
[TBL] [Abstract][Full Text] [Related]
2. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
3. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
Eriguchi T; Takeda A; Sanuki N; Oku Y; Aoki Y; Shigematsu N; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1006-11. PubMed ID: 23102838
[TBL] [Abstract][Full Text] [Related]
4. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
5. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
[TBL] [Abstract][Full Text] [Related]
6. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
[TBL] [Abstract][Full Text] [Related]
7. Myositis following spine radiosurgery for metastatic disease: a case series.
Lockney DT; Jia AY; Lis E; Lockney NA; Liu C; Hopkins B; Higginson DS; Yamada Y; Laufer I; Bilsky M; Schmitt AM
J Neurosurg Spine; 2018 Apr; 28(4):416-421. PubMed ID: 29372858
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Reshko LB; Baliga S; Crandley EF; Harry Lomas IV; Richardson MK; Spencer K; Bennion N; Mikdachi HE; Irvin W; Kersh CR
Gynecol Oncol; 2020 Dec; 159(3):611-617. PubMed ID: 33059914
[TBL] [Abstract][Full Text] [Related]
9. A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses.
Liauw SL; Ni L; Wu T; Arif F; Cloutier D; Posner MC; Kozloff M; Kindler HL
J Gastrointest Oncol; 2020 Dec; 11(6):1399-1407. PubMed ID: 33457009
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute.
Prendergast BM; Dobelbower MC; Bonner JA; Popple RA; Baden CJ; Minnich DJ; Cerfolio RJ; Spencer SA; Fiveash JB
Radiat Oncol; 2013 Nov; 8():273. PubMed ID: 24256563
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
12. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract.
Osmundson EC; Wu Y; Luxton G; Bazan JG; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):986-94. PubMed ID: 25659885
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Adverse Gastrointestinal Events After Stereotactic Body Radiation Therapy for Liver Tumors.
Ohmatsu K; Hashimoto Y; Kuribayashi S; Toramatsu C; Lee K; Kono S; Kawanishi M; Karasawa K
Cancer Diagn Progn; 2023; 3(1):91-95. PubMed ID: 36632598
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy for gastrointestinal malignancies.
Minn AY; Koong AC; Chang DT
Front Radiat Ther Oncol; 2011; 43():412-427. PubMed ID: 21625166
[TBL] [Abstract][Full Text] [Related]
16. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
Lin YW; Lin LC; Lin KL
Front Oncol; 2014; 4():278. PubMed ID: 25401085
[TBL] [Abstract][Full Text] [Related]
17. Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy.
Gomez DR; Hunt MA; Jackson A; O'Meara WP; Bukanova EN; Zelefsky MJ; Yamada Y; Rosenzweig KE
Radiother Oncol; 2009 Dec; 93(3):414-8. PubMed ID: 19923027
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
19. Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model.
Duijm M; van der Voort van Zyp NC; van de Vaart P; Oomen-de Hoop E; Mast ME; Hoogeman MS; Nuyttens JJ
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):73-81. PubMed ID: 31499137
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning.
Nguyen TK; Sahgal A; Dagan R; Eppinga W; Guckenberger M; Kim JH; Lo SS; Redmond KJ; Siva S; Stish BJ; Tseng CL
Pract Radiat Oncol; 2020; 10(6):e452-e460. PubMed ID: 32171852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
